USE OF INTERLEUKIN-22 IN THE TREATMENT OF FATTY LIVER DISEASE
The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided.
1 . A method for treatment of fatty liver, wherein said method comprises administering to a subject in need of treatment a composition, said composition comprises a pharmaceutically effective amount of IL-22.
2 . The method according to claim 1 , wherein said composition reduces steatosis.
3 . The method according to claim 1 , wherein said composition decreases serum triglyceride level.
4 . The method according to claim 1 , wherein said composition decreases transaminase level.
5 . The method according to claim 1 , wherein said IL-22 is human IL-22.
6 . The method according to claim 1 , wherein said IL-22 is encoded by the polynucleotide of SEQ ID NO. 1.
7 . The method according to claim 1 , wherein said fatty liver disease is alcoholic fatty liver disease or non-alcoholic fatty liver disease.
8 . The method according to claim 1 , wherein said composition reduces body weight.
9 . The method according to claim 1 , wherein said composition reduces liver weight.
10 . The method according to claim 1 , wherein the pharmaceutically effective amount of IL-22 is 10 μg/kg/d-300 μg/kg/d in a mammal.
11 . The method according to claim 1 , wherein the pharmaceutically effective amount of IL-22 is 10 μg/kg/d-100 μg/kg/d in a mammal.